Anebulo PharmaceuticalsANEB
13F holders, Q3 2024 (September 30)13holders
1new positions
1sold out
$1.93avg. 13F price*
At the end of Q3 2024, 13 institutions reported holding Anebulo Pharmaceuticals Inc. (ANEB) in their 13F filings, unchanged from Q2 2024. 1 opened new positions and 1 sold out. The largest holders were 22NW, LP ($10.4M), LVW Advisors, LLC ($1.2M) and Nantahala Capital Management, LLC ($986K).
- Company
- Anebulo Pharmaceuticals Inc.
- CUSIP
- 034569103
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $1K |
| Exits | 1 | $0 |
All 13F filers, Q2 2024 → Q3 2024: 37,419 shares bought and 1,658 shares sold, net +35,761 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 13 holders
| 22NW, LP | 8.68% | No change | 5,366,290 | $10.4M |
| LVW Advisors, LLC | 0.16% | Reduce -0.2% | 641,039 | $1.2M |
| Nantahala Capital Management, LLC | 0.08% | No change | 511,073 | $986K |
| Morgan Stanley | 0.00% | No change | 399,219 | $770K |
| Ikarian Capital, LLC | 0.09% | No change | 157,862 | $305K |
| Vanguard Group Inc. | 0.00% | Add +0.1% | 154,036 | $297K |
| Geode Capital Management, LLC | 0.00% | Add +71.1% | 87,790 | $169K |
| Boothbay Fund Management, LLC | 0.00% | No change | 18,978 | $37K |
| BlackRock, Inc. | 0.00% | — | 3,905 | $8K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -18.4% | 2,694 | $5K |
| UBS Group AG | 0.00% | New | 763 | $1K |
| Bank of America Corp. | 0.00% | Add +16.9% | 76 | $147 |
| JPMorgan Chase & Co. | 0.00% | Reduce -10.0% | 9 | $17 |
"% of holder's portfolio" is ANEB's weight in each manager's 13F, not the share of Anebulo Pharmaceuticals Inc. the manager owns.